57%

Novo Nordisks Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas

Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke…

4 days ago

Diginex Limited Announces 57% Increase in Revenues and Transformed Balance Sheet for Fiscal Year ended March 31, 2025

LONDON, July 11, 2025 (GLOBE NEWSWIRE) -- Diginex Limited (“Diginex” or the “Company”) (NASDAQ: DGNX), a leading provider of Sustainability…

2 months ago